Form 4: ResMed Director Harjit Gill Receives RSU Grant

ResMed Inc. Director Harjit Gill was granted 1,073 Restricted Stock Units, increasing beneficial ownership to 10,940 shares.

Summary

• Harjit Gill, a Director of ResMed Inc. (RMD), acquired 1,073 shares of ResMed Common Stock.
• The transaction occurred on November 20, 2025.
• These shares represent Restricted Stock Units (RSUs) granted at a price of $0.
• Following this transaction, Harjit Gill beneficially owns a total of 10,940 shares.
• The RSUs will vest in full on the earlier of November 11, 2026, or the annual meeting of stockholders in the year following the grant date.

Sentiment

Score: 7

Explanation: The grant of Restricted Stock Units to a director is a positive signal of continued alignment between management and shareholder interests, though it is a routine compensation event.

Positives

• The grant of Restricted Stock Units (RSUs) to Director Harjit Gill aligns management's interests with those of shareholders.
• The increase in beneficial ownership to 10,940 shares demonstrates continued commitment to the company.

Negatives

• No negative aspects are indicated in this routine insider transaction filing.

Risks

• No specific risks are mentioned in this Form 4 filing.

Future Outlook

The granted Restricted Stock Units are scheduled to vest in full on the earlier of November 11, 2026, or the annual meeting of stockholders in the year following the grant date, indicating a future equity payout contingent on continued service.

Management Comments

• No direct management comments or quotes are provided in this Form 4 filing.

Industry Context

The grant of Restricted Stock Units to a director is a standard practice in corporate governance and executive compensation across various industries, including medical device companies like ResMed. It serves to incentivize long-term performance and align the interests of directors with those of shareholders.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a form of director compensation is a common practice among publicly traded companies, including peers in the medical technology sector such as Medtronic (MDT), Stryker (SYK), and Intuitive Surgical (ISRG).
• The grant size of 1,073 RSUs for a director is within typical ranges for non-executive director compensation, which often includes a mix of cash and equity to ensure alignment with shareholder value creation.
• The vesting schedule, tied to a future date or annual meeting, is standard for encouraging long-term commitment and retention, consistent with corporate governance best practices observed in companies of similar market capitalization.

Related Party Transactions

• This filing details an equity grant to a director, which is an insider transaction related to compensation, not a transaction with a separate related party entity.

Stakeholder Impact

• Shareholders: Positive impact due to increased alignment of director's interests with long-term company performance.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• The Restricted Stock Units will vest on the earlier of November 11, 2026, or the annual meeting of stockholders in the year following the grant date.

Key Dates

Keywords

ResMed Inc., RMD, Harjit Gill, Director, Restricted Stock Units, RSU, Insider Transaction, Beneficial Ownership, Equity Grant, Compensation